POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit

Ac Schuh,K Pratz,J Lachaine,Hs Suh,X Li,X Chai,J Xie,C Gu,Cn Bui

doi:10.1016/j.jval.2021.11.194

POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit

Ac Schuh, K Pratz + Show 7 more

Open Access

https://doi.org/10.1016/j.jval.2021.11.194

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research	Publication Date: Jan 1, 2022
License type: elsevier-specific: oa user license

Affiliation: Princess Margaret Cancer Centre, Hospital of the University of Pennsylvania, Kyung Hee University, China National Health Development Research Center, Analysis Group (United States)

#Newly Diagnosed Acute Myeloid Leukemia #Acute Myeloid Leukemia Who + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

The VIALE-A/C studies showed that venetoclax combination therapies improved overall survival (OS) and event-free survival (EFS) in patients with newly diagnosed acute myeloid leukemia (ND-AML) ineligible for intensive chemotherapy. The study aims to assess the long-term benefits of venetoclax+azacitidine (AZA)/low-dose cytarabine (LDAC) versus monotherapy AZA, LDAC, decitabine and best supportive care (BSC).

Full Text